Reporting from AACR 2023, Jeffrey S. Weber presents the results from primary analysis of the KEYNOTE-942 trial, testing a combination of pembrolizumab plus a novel mRNA-based vaccine based on personalised neoantigens from patients with high-risk resected melanoma, compared to pembrolizumab alone. The combined therapy showed an encouraging 44% reduction in the risk of recurrence or death. It’s the first successful cancer vaccine trial in melanoma but a larger confirmatory study is needed.

Abstract: CT001 - A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial

Also in this #AACR23 highlights video series, you can find:

Robin Katie Kelley discussing the phase III KEYNOTE-966 study evaluating the combination of pembrolizumab with gemcitabine and cisplatin versus gem/cis alone in patients with previously untreated advanced biliary tract cancer. Longer overall survival and duration of response validate the role of immune checkpoint inhibition in combination with chemotherapy as first-line treatment option that improves outcomes in these patients.
[ Ссылка ]

John V. Heymach discusses the EFS and pCR results from the AEGEAN trial testing neoadjuvant durvalumab plus platinum-based chemotherapy and followed after surgery with adjuvant durvalumab versus neoadjuvant placebo plus platinum-based chemotherapy in treatment-naïve patients with early stage resectable NSCLC. This is the first phase III trial to demonstrate the benefit of perioperative immunotherapy plus neoadjuvant chemotherapy in this setting.
[ Ссылка ]

Pierce Chow discussing results of the IMbrave050 trial testing adjuvant atezolizumab plus bevacizumab versus active surveillance in high-risk hepatocellular carcinoma (HCC). This is landmark, the first trial of adjuvant treatment for HCC to show RFS improvement following resection or ablation. Longer follow-up is needed to evaluate if the difference observed in relapse occurence will translate into a longer survival.
[ Ссылка ]

You can find more expert videos on our OncologyPRO website: The home of ESMO’s educational and scientific resources.
[ Ссылка ]





Produced by the European Society for Medical Oncology
[ Ссылка ]

свернуть